The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib, open-label study of add on therapy with CK0804 in participants with myelofibrosis, with suboptimal response to ruxolitinib.
 
Lucia Masarova
No Relationships to Disclose
 
Meixian Huang
No Relationships to Disclose
 
Tapan M. Kadia
Honoraria - CURE
Consulting or Advisory Role - Abbvie/Genentech; Agios; Daiichi Sankyo/UCB Japan; Jazz Pharmaceuticals; Liberum; Novartis; Pfizer; Pinot Bio; Sanofi; SERVIER
Research Funding - Amgen; Ascentage Pharma; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; BiolineRx; Bristol-Myers Squibb; Celgene; cellenkos; Cyclacel; Delta-Fly Pharma; Genentech/Abbvie; Genfleet Therapeutics; Glycomimetics; Incyte; Iterion Therapeutics; Jazz Pharmaceuticals; Pfizer; Pulmotech; Regeneron (Inst)
 
Naveen Pemmaraju
Employment - MD Anderson Cancer Center
Leadership - ASCO; ASH
Consulting or Advisory Role - Abbvie; Aplastic Anemia and MDS International Foundation; Aptitude Health; Astellas Pharma; Blueprint Medicines; Bristol Myers Squibb; CancerNet; CareDx; Celgene; Cimeio Therapeutics; Clearview Healthcare Partners; CTI BioPharma Corp; Curio Science; Dava Oncology; EUSA Pharma; Harborside Press; Imedex; Immunogen; Intellisphere; Intellisphere; Magdalen Medical Publishing; Medscape; Menarini Group; Neopharm; Novartis; OncLive; Pacylex; Patient Power; Peerview; Pharmaessentia; Physicans' Education Resource
Research Funding - US DOD (Inst)
Other Relationship - Karger Publishers
(OPTIONAL) Uncompensated Relationships - Dan's House of Hope; Oncology Times
 
Naval Guastad Daver
Consulting or Advisory Role - Abbvie; Agios; Amgen; Arog; Astellas Pharma; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Genentech; Gilead Sciences; Immunogen; Jazz Pharmaceuticals; Kite, a Gilead company; Novartis; Pfizer; SERVIER; Shattuck Labs; Stemline/Menarini; Syndax; Trillium Therapeutics
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); FATE Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Glycomimetics (Inst); Hanmi (Inst); Immunogen (Inst); Kite, a Gilead company (Inst); Novimmune (Inst); Pfizer (Inst); Servier (Inst); Trillium Therapeutics (Inst); Trovagene (Inst)
 
Mi-Ae Lyu
No Relationships to Disclose
 
Ke Zeng
No Relationships to Disclose
 
Tara Sadeghi
Employment - cellenkos
Leadership - cellenkos
Stock and Other Ownership Interests - cellenkos
Travel, Accommodations, Expenses - cellenkos
 
Ekatherine Asatiani
Employment - Incyte
Stock and Other Ownership Interests - Incyte
Travel, Accommodations, Expenses - Incyte
 
Simrit Parmar
Stock and Other Ownership Interests - cellenkos; cellenkos (Inst)
Research Funding - cellenkos; cellenkos (Inst)
Patents, Royalties, Other Intellectual Property - cellenkos; cellenkos (Inst)
 
Christopher Flowers
Stock and Other Ownership Interests - Foresight Diagnostics; N Power
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb/Celgene; Celgene; Curio Science; Denovo Biopharma; Epizyme; Foresight Diagnostics; Genentech/Roche; Genmab; Gilead Sciences; Karyopharm Therapeutics; MorphoSys; Pharmacyclics/Janssen; SeaGen; Spectrum Pharmaceuticals
Research Funding - 4D Pharma (Inst); Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Alimera Sciences (Inst); Amgen (Inst); Bayer (Inst); Celgene (Inst); Cellectis (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Guardant Health (Inst); Iovance Biotherapeutics (Inst); Janssen Oncology (Inst); Kite/Gilead (Inst); Millennium (Inst); MorphoSys (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Sanofi (Inst); Takeda (Inst); TG Therapeutics (Inst); Xencor (Inst); ZIOPHARM Oncology (Inst)
 
Srdan Verstovsek
Consulting or Advisory Role - Celgene; Constellation Pharmaceuticals; Incyte; Novartis; Sierra Oncology
Research Funding - AbbVie (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Galecto (Inst); Geron (Inst); Incyte (Inst); Kartos Therapeutics (Inst); PharmaEssentia (Inst); Protagonist Therapeutics (Inst); Sierra Oncology (Inst); Telios (Inst)